These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. The expression of p53 and bcl-2 in superficial bladder transitional cell carcinoma and its role in the outcome of postoperative intravesical chemotherapy. Tzai TS; Chow NH; Lin JS; Yang WH; Tong YC Anticancer Res; 1998; 18(6B):4717-21. PubMed ID: 9891547 [TBL] [Abstract][Full Text] [Related]
5. Cyclin D1 expression in transitional cell carcinoma of the bladder: correlation with p53, waf1, pRb and Ki67. Tut VM; Braithwaite KL; Angus B; Neal DE; Lunec J; Mellon JK Br J Cancer; 2001 Jan; 84(2):270-5. PubMed ID: 11161387 [TBL] [Abstract][Full Text] [Related]
6. Prognostic value of p53 and MIB-1 in transitional cell carcinoma of the urinary bladder with regional lymph node involvement. Frank I; Cheville JC; Blute ML; Lohse CM; Karnes RJ; Weaver AL; Sebo TJ; Nehra A; Zincke H Cancer; 2004 Oct; 101(8):1803-8. PubMed ID: 15386300 [TBL] [Abstract][Full Text] [Related]
7. Expression of the epidermal growth factor receptor and Her-2 are predictors of favorable outcome and reduced complete response rates, respectively, in patients with muscle-invading bladder cancers treated by concurrent radiation and cisplatin-based chemotherapy: a report from the Radiation Therapy Oncology Group. Chakravarti A; Winter K; Wu CL; Kaufman D; Hammond E; Parliament M; Tester W; Hagan M; Grignon D; Heney N; Pollack A; Sandler H; Shipley W Int J Radiat Oncol Biol Phys; 2005 Jun; 62(2):309-17. PubMed ID: 15890569 [TBL] [Abstract][Full Text] [Related]
8. p53 and RB expression predict progression in T1 bladder cancer. Grossman HB; Liebert M; Antelo M; Dinney CP; Hu SX; Palmer JL; Benedict WF Clin Cancer Res; 1998 Apr; 4(4):829-34. PubMed ID: 9563875 [TBL] [Abstract][Full Text] [Related]
9. Superficial (pT2a) and deep (pT2b) muscle invasion in pathological staging of bladder cancer following radical cystectomy. Yu RJ; Stein JP; Cai J; Miranda G; Groshen S; Skinner DG J Urol; 2006 Aug; 176(2):493-8; discussion 498-9. PubMed ID: 16813876 [TBL] [Abstract][Full Text] [Related]
10. Expression of cell cycle proteins in T1a and T1b urothelial bladder carcinoma and their value in predicting tumor progression. Mhawech P; Greloz V; Oppikofer C; Szalay-Quinodoz I; Herrmann F Cancer; 2004 Jun; 100(11):2367-75. PubMed ID: 15160340 [TBL] [Abstract][Full Text] [Related]
11. P53 expression in small cell carcinoma of the urinary bladder: biological and prognostic implications. Wang X; Jones TD; Maclennan GT; Yang XJ; Lopez-Beltran A; Eble JN; Koch MO; Lin H; Baldridge LA; Tretiakova M; Cheng L Anticancer Res; 2005; 25(3B):2001-4. PubMed ID: 16158936 [TBL] [Abstract][Full Text] [Related]
12. p53 and p21 Expression levels predict organ preservation and survival in invasive bladder carcinoma treated with a combined-modality approach. Garcia del Muro X; Condom E; Vigués F; Castellsagué X; Figueras A; Muñoz J; Solá J; Soler T; Capellà G; Germà JR Cancer; 2004 May; 100(9):1859-67. PubMed ID: 15112266 [TBL] [Abstract][Full Text] [Related]
13. [Expression of bcl-2 and p16 in transitional cell carcinoma of urinary bladder]. Leng J; Zhang Y; Yao X; Wen K Zhonghua Wai Ke Za Zhi; 2000 Jan; 38(1):40-3. PubMed ID: 11831985 [TBL] [Abstract][Full Text] [Related]
14. Altered retinoblastoma protein expression in nonsmall cell lung cancer: its synergistic effects with altered ras and p53 protein status on prognosis. Dosaka-Akita H; Hu SX; Fujino M; Harada M; Kinoshita I; Xu HJ; Kuzumaki N; Kawakami Y; Benedict WF Cancer; 1997 Apr; 79(7):1329-37. PubMed ID: 9083154 [TBL] [Abstract][Full Text] [Related]
15. P16 immunoreactivity is an independent predictor of tumor progression in minimally invasive urothelial bladder carcinoma. Krüger S; Mahnken A; Kausch I; Feller AC Eur Urol; 2005 Apr; 47(4):463-7. PubMed ID: 15774242 [TBL] [Abstract][Full Text] [Related]
16. Minichromosome maintenance proteins 2 and 5 expression in muscle-invasive urothelial cancer: a multivariate survival study including proliferation markers and cell cycle regulators. Korkolopoulou P; Givalos N; Saetta A; Goudopoulou A; Gakiopoulou H; Thymara I; Thomas-Tsagli E; Patsouris E Hum Pathol; 2005 Aug; 36(8):899-907. PubMed ID: 16112007 [TBL] [Abstract][Full Text] [Related]
17. Combined effects of p53, p21, and pRb expression in the progression of bladder transitional cell carcinoma. Chatterjee SJ; Datar R; Youssefzadeh D; George B; Goebell PJ; Stein JP; Young L; Shi SR; Gee C; Groshen S; Skinner DG; Cote RJ J Clin Oncol; 2004 Mar; 22(6):1007-13. PubMed ID: 14981105 [TBL] [Abstract][Full Text] [Related]
18. Correlation of abnormal RB, p16ink4a, and p53 expression with 3p loss of heterozygosity, other genetic abnormalities, and clinical features in 103 primary non-small cell lung cancers. Geradts J; Fong KM; Zimmerman PV; Maynard R; Minna JD Clin Cancer Res; 1999 Apr; 5(4):791-800. PubMed ID: 10213214 [TBL] [Abstract][Full Text] [Related]
19. Abnormal bcl-2 and pRb expression are independent correlates of radiation response in muscle-invasive bladder cancer. Pollack A; Wu CS; Czerniak B; Zagars GK; Benedict WF; McDonnell TJ Clin Cancer Res; 1997 Oct; 3(10):1823-9. PubMed ID: 9815569 [TBL] [Abstract][Full Text] [Related]
20. p53 nuclear accumulation is not associated with decreased disease-free survival in patients with node positive transitional cell carcinoma of the bladder. Fleshner N; Kapusta L; Ezer D; Herschorn S; Klotz L J Urol; 2000 Oct; 164(4):1177-82. PubMed ID: 10992361 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]